

AD_____

Award Number: DAMD17-03-C-0088

TITLE: Structure-Based Design of Inhibitors to the Cytotoxin
Ricin

PRINCIPAL INVESTIGATOR: Jon D. Robertus, Ph.D.

CONTRACTING ORGANIZATION: University of Texas at Austin
Austin, Texas 78713-7726

REPORT DATE: July 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2004	3. REPORT TYPE AND DATES COVERED Annual (15 Jun 2003 - 14 Jun 2004)	
4. TITLE AND SUBTITLE Structure-Based Design of Inhibitors to the Cytotoxin Ricin			5. FUNDING NUMBERS DAMD17-03-C-0088	
6. AUTHOR(S) Jon D. Robertus, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Texas at Austin Austin, Texas 78713-7726 <i>E-Mail:</i> jrobertus@mail.utexas.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) Ricin is a cytotoxin and a known bioterrorist weapon. The Army is pursuing anti-ricin vaccines, but plans to develop an efficacious antidote to the toxin, for cases where vaccination is not appropriate. The goal of this project is use the X-ray structure of ricin A chain (RTA) as a template for inhibitor design. Computer modeling and X-ray screening aid in the design process. Inhibitors which bind to the RTA substrate specificity site have been identified. A previous platform, 9-oxoguanine, has been shown to be of limited synthetic utility, however, 9-deaguanine appears to be a more versatile specificity site platform and should allow a range of pendant additions. A search has been initiated to screen for pendants which can be attached to the platform and which make strong and specific interactions at other sites. These groups can aid inhibitor uptake, binding specificity, and binding strength. A new compound, based on aminimide synthesis, was tested just as this report was being prepared. It has an IC ₅₀ more than 1000 times as potent as any past inhibitors we have tested; this finding will cause us to modify our research direction to some extent.				
14. SUBJECT TERMS Ricin, inhibitor design, x-ray structure, novel compounds			15. NUMBER OF PAGES 18	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

20041021 013

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	5
Task 1.....	7
Task 2.....	12
Task 3.....	15
Key Research Accomplishments.....	16
Reportable Outcomes.....	16
Conclusions.....	16
References.....	17
Appendices.....	

INTRODUCTION

This contracted project is aimed at designing, synthesizing, and testing small molecule inhibitors of the cytotoxin ricin. Ricin is a class B biological agent which is known to be in the possession of terrorist groups (Loyd and Fletcher, 2001). Although not as menacing as infectious agents, ricin is of great concern because of the ease with which large amounts of semi pure material can be produced (Wellner, et al, 1995). The Army is proceeding with vaccine development for key military personnel (Olson et al, 2004). However, wide spread vaccination of the military or civilian population is not practical or desirable, and so there is a need for an efficacious antidote. In addition to its utility such a compound could reduce panic that arises from a relatively minor terrorist incident. Our area of expertise is the rational design of inhibitors of enzymes like ricin A chain (RTA). We have elucidated the three-dimensional structure of ricin and this model serves as a template for the design of small molecules that can bind tightly and inactivate the toxin. These inhibitor compounds should also incorporate elements of drug design, including solubility, stability, and low toxicity. We have used computer searches to identify classes of inhibitors that act as "platform" molecules. These platforms have been modified and appended creating novel inhibitors for RTA. This particular project is a collaboration between structural biologists (Robertus group) and synthetic chemists (Kerwin group) to extend our previous research efforts on antidotes. It is a step-wise process, beginning with modest inhibitors, which are then sequentially improved after analysis, to produce ever more potent compounds; the program is scheduled to last three years. Our overall goal is to create a ricin inhibitor which is efficacious at inhibiting ricin intoxication of cultured cells, and itself is non-toxic. Since an aerosol dispersion is considered the most likely form of attack we (Kehrer group) will use cultured human lung cells for this test.

BODY

The original Statement of Work (SOW) is as follows:

Task 1: Design improved specificity pocket (months 1 - 12)

- a. Prepare 9-oxaguananine
- b. Prepare other related heterocycles

Task 2: Identify ligands for second ricin binding pocket (months 1 - 18)

- a. Use computer searches based on ricin structure
- b. Apply crystallographic screening of shape-diverse sets of commercial compounds

Task 3: Prepare tripartite inhibitors joining best specificity pocket and second pocket moieties with appropriate linkers (months 9-24).

Task 4: Use iterative crystallographic algorithm to refine tripartite inhibitors (months 12-36)

- a. Modify compound shape to fit enzyme contours
- b. Design compounds for maximum water solubility and biological uptake

Task 5: Test biological efficacy of inhibitors as ricin antidotes (months 1-36)

- a. Candidate inhibitors will be tested against ricin enzyme activity
- b. Ricin inhibitors will be tested for protective action in cultured human lung cells
- c. The most promising ricin antidotes will be sent to a commercial testing facility for initial human safety tests using a panel of enzyme and receptor assays.

ACCOMPLISHMENTS FOR YEAR 1

Year one efforts are primarily concerned with Tasks 1 and 2 in the SOW, although a start has been made on Task 3. In addition, we needed to modify the RTA enzyme assay, which can be called Task 0.

TASK 0: Modifying and recalibrating the ricin enzyme assay.

In the past our laboratory has measured ricin activity by its ability to inhibit the synthesis of radiolabeled poly Phe on ribosomes from *A. salina*, using transcription factors purified from wheat germ (Ready et al, 1983). When we restarted work on RTA inhibitors we found this assay was no longer feasible. We investigated commercial protein synthesis kits centered around rabbit reticulocyte ribosomes, testing several messages. However because of cost and ease of use we adopted the simplest assay in which reticulocyte ribosomes express natural hemoglobin message. Because the ribosomes are preloaded with message, and may form RTA resistant polysomes, even the most aggressive attacks by RTA cannot eliminate all background synthesis. However, the background rate is controllable and a simple dose response for a 30' incubation of RTA with the reticulocyte system at 30 °C is shown in Figure 1. The IC₅₀ for RTA is 0.15 nM, which compares favorably with the value of 0.3 nM seen previously with the *A. salina* system (Ready et al, 1991).

To further confirm the utility of the new system, we used it to measure the inhibition of RTA by pterotic acid (PTA), a known inhibitor of the enzyme. For this test we fixed the concentration of RTA at 0.15 nM. The results are shown in Figure 2. The IC_{50} of PTA for RTA is about 0.55 mM, which, again, compares favorably with the value of 0.6 mM seen with the *A. salina* system (Yan et al, 1997).

Finally, we used the new assay to measure the inhibition of RTA by 8-methyl-9-oxoguanine (9OG). This novel compound of our design had been the most potent small molecule "platform" inhibitor previously tested (Miller et al, 2002). 9OG was resynthesized just prior to testing and the results are shown in Figure 3. The IC_{50} is roughly 40 μ M, about 10 times better than the 400 μ M reported earlier (Miller et al, 2002).




Figure 3: Inhibition of RTA by pterotic acid in the reticulocyte assay.

RTA activity. This assay has been used by others for qualitative measures of N-glycosidase action (Endo et al, 1987). We observed that some potential RTA inhibitors can also inhibit ribosomes, thereby rendering the protein synthesis assay useless (Miller et al, 2002). The aniline cleavage assay only depends on the 28S rRNA being intact; depurination by ricin renders the chain susceptible to aniline cleavage which can be observed as a novel band on an acrylamide gel. We used yeast ribosomes as a source of rRNA and showed a dose response activity of RTA against it. Our experiments (not shown) suggest that the aniline assay can only give qualitative results. That is, it might be able to rank order inhibitor strengths, but it is too noisy to give reliable IC_{50} measures.




Figure 1: A dose response curve for RTA against a commercial reticulocyte lysate kit.





Figure 2: Inhibition of RTA with 9OG using the reticulocyte assay.

TASK 1: Design improved specificity pocket ligands (months 1-12)

A substantial portion of the synthetic work carried out over the last 12 months has focused on the construction of heterocyclic scaffolds that have been predicted to bind to the specificity pocket of the catalytic ricin A-chain. These efforts have resulted in the preparation of examples of an entirely new class of heterocycles (7-deaza-9-oxaguanines), a previously reported versatile intermediate for the preparation of 7-substituted-9-deazaguanines, and numerous precursors to substituted 9-oxaguanine derivatives. However, we have been unable to prepare any 9-oxaguanine other than our previously reported 8-methyl-substituted analogue. At this point, we have not been able to improve upon this specificity pocket ligand.

A. Prepare 9-oxaguanine analogues



Our previous work had demonstrated that 8-methyl-9-oxa-guanine (**1**, R = Me, Scheme 1) inhibits ricin by binding to the specificity pocket. While the inhibition constant for 8-methyl-9-oxa-guanine was rather weak, we believe that analogs that contained more suitable side chains will be more effective inhibitors. Two potential approaches to the 9-oxa-guanine ring system were proposed (Scheme 1). In one approach, an acylated diaminohydroxypyrimidine (**2**) undergoes cyclodehydration to form the oxazole ring of the 9-oxa-guanine heterocycle. In another approach, the oxazole ring is constructed first (**3**), and the pyrimidine ring is subsequently elaborated. We




Table 1. Preparation of 5-acylamino-2-amino-4-hydroxypyrimidines

	5, R =	Conditions	Yield 6	Yield 2
a	CH ₂ CH ₂ Ph	K ₂ CO ₃ , CH ₂ Cl ₂	98%	22%
b	CH(CH ₃) ₂	NaHCO ₃ , ether/H ₂ O	92.5%	82%
c		Et ₃ N, THF	85%	71%
d		Et ₃ N, THF	79%	58%
e	CH ₂ NHBoc	DCC, HOBT, THF*	82%	64%
f		DCC, CH ₂ Cl ₂ *	63%	n/a

* from the corresponding carboxylic acid.

have examined each of these routes, as described below. The preparation of the methyl substituted 9-oxa-guanine derivative (**1**, R = Me) was originally carried out through cyclodehydration of the 5-acetamido-2-amino-4-hydroxypyrimidine (**2**, R = Me). A variety of cyclodehydration conditions were tried, but heating the solid acylaminopyrimidine (**2**, R = Me) under vacuum and collecting the product by sublimation was the only method that was found to reproducibly afford 8-methyl-9-oxaguanine (**1**, R = Me) in useful yields. Thus, our original efforts focused on this







Table 2. Attempted cyclodehydration of 5-acylamino-2-amino-4-hydroxypyrimidines.

	2, R =	Conditions
a	CH ₂ CH ₂ Ph	300 °C, 0.8 mm Hg, 24 h or 280–300 °C, 1 atm Ar, 14 h
b	CH(CH ₃) ₂	280–300 °C, 0.8 mm Hg, 18 h or POCl ₃ , reflux, 8 h or PPA, 120–150 °C, 8–14 h
c		300 °C, 0.8 mm Hg, 20 h or PPA, 70–180 °C, 8 h
d		280–300 °C, 0.8 mm Hg, 18 h

procedure, starting with a variety of 5-acylamino-2-amino-4-hydroxypyrimidines **2** (Table 1). Despite our previous successful cyclodehydration of 5-acetamido-2-amino-4-hydroxypyrimidine (**2**, R = Me) to 8-methyl-9-oxa-guanine (**1**, R = Me), we have been unable to prepare any other 9-oxaguanine analogs through this route (Table 2). One possible reason that the sublimation conditions that were successful in affording 8-methyl-9-oxaguanine fail in the other cases due to the decreased volatility of the 9-oxaguanines. That is, if any of these 9-oxa-guanine derivatives form, they decompose at the temperatures required for their


sublimation. Thus, we turned to alternate procedures, including heating solid **2** under



an atmosphere of argon or under vacuum, or cyclodehydration of **2** with polyphosphoric acid (PPA) or phosphorous oxychloride; however, none of these methods were successful (Table 2).

We next turned to the alternative route to these 9-oxaguanine derivatives, which involves elaborating the pyrimidine ring after formation of the oxazole ring. This route has some precedence in the literature, (Patil et al, 1971; Turchi et al, 1983; Sekeya et al, 1990) but no cases have been reported in which 2-amino-substituted heterocycles (such as **1**) were formed. Our efforts have currently focused on intermediate 4-carboxy-5-ethoxyoxazoles. Thus, the acylated aminomalonate **2b** undergoes cyclodehydration with PCl₅ in refluxing chloroform to afford the oxazole **7**, which is subjected to careful hydrolysis with LiOH to give the carboxylic acid **8** (Scheme 2). Our initial efforts to couple this carboxylic acid with guanidine, followed by cyclization have not been



successful. We will continue this approach by exploring other coupling methods, including direct coupling of ethyl ester **7** with guanidine in sodium methoxide/methanol. As shown in Scheme 3, we have also met some difficulty in formation of other oxazoles. Despite the successful conversion of **2b** to **7** with PCl_5 , the aminomalonate derivative **2d** did not afford the oxazole **9** under similar conditions. We have begun to explore alternative routes to the oxazole **9**. Attempts to brominate **2d** did not afford the bromomalonate **10**;



rather, electrophilic aromatic bromination takes place. Our plan is to employ a free radical initiator such as AIBN in this reaction in the future in order to bias the products towards those derived from free radical bromination. We have also begun to construct precursors to more elaborate oxazoles.

The acylaminomalonate **6f** (Table 1) has been prepared and will be subjected to cyclodehydration or bromination/cyclization conditions in order to afford the corresponding oxazole.

If we continue to have difficulty with this route to 9-oxa-guanine derivatives, we will explore an alternative route from 4-amino-oxazole derivatives (**3**, $\text{Y} = \text{NH}_2$, Scheme 1). These can be prepared from the corresponding aminocyanomalonates, as shown below for **11**, which we have used to prepare the amino-oxazole **12** (Scheme 4). Such amino-oxazoles will be treated with a formamidinylating reagent to give the substituted guanidines **13**, which will undergo cyclization to 9-oxa-guanines **1**. Alternatively, conversion of these to phosphorimides followed by reaction with trimethylsilylisocyanate may give the carbodiimides **14**, which may cyclize to 9-




oxa-guanines upon treatment with ammonia (Scheme 4).

Finally, we are exploring an alternative route to 8-substituted 9-oxa-guanine derivatives through the 8-methyl compound **1**. We will protect the exocyclic amino group of **1** as the pivaloyl amide **15** (Scheme 5), followed by free-radical bromination of the methyl group to afford the bromomethyl derivative **16**. This bromomethyl derivative can then be elaborated to afford a variety of 8-substituted-9-oxa-guanine derivatives (**17**) Scheme 5.

B. Prepare other related heterocycles


i) 9-Deazaguanine derivatives.

We had also identified 9-deazaguanine as a promising platform inhibitor for ricin; however, we wanted to prepare substituted analogs in order to probe the effect of substituents on the orientation of the compound in the specificity site as well as the




affinity for ricin. We have prepared the key intermediate **24** (Scheme 6), following the route of Taylor and Young (Taylor and Young, 1995). Alkylation of **24** with a variety of alkylhalides (R-X) followed by NaOH deprotection should afford the 7-substituted 9-deazaguanine derivatives **26**. Our initial attempts using the alkylbromide **27** have been met with very low yields of alkylated product, due to the facile elimination of HBr from this compound under the alkylation conditions. We are optimizing the reaction conditions employing **27**, as well as exploring a variety of alternative alkylhalides in this reaction.

ii). 9-Oxa-7-deaza-guanines




A series of 7-deaza-9-oxaguanine analogs (2-amino-3*H*-furo[2,3-*d*]pyrimidin-4-ones) have been prepared in order to explore this heterocyclic framework as an alternative platform for ricin inhibition. Condensation of chloroacetaldehyde or ethyl chloroformate with 2-amino-4,6-dihydroxypyrimidine (**28**) affords the corresponding 8-substituted 7-deaza-9-oxaguanines **29** and **30** (Scheme 7). In a related reaction, condensation of ethyl chloroformate with 2,4-diamino-6-hydroxypyrimidine (**31**) affords the 9-substituted 7-deaza-9-oxaguanine **32** (Scheme 7).



C. Prepare Aminimides

Hydroxyethyl aminimides can be prepared via a three component condensation reaction involving an ester, a 1,1-disubstituted hydrazine, and an epoxide (Slagel, 1968). The resulting aminimides are stable zwitterionic compounds that are water soluble. Due to their structural similarity to peptides, aminimides have been employed as peptide isosteres in the design of inhibitors of proteases (Rutenber et al, 1996; Peisach, 1995). Our interest in these compounds derived from their favorable solubility; we reasoned that the construction of platform heterocycles targeting the ricin specificity pocket with aminimide side chains would lead to both increase affinity for ricin as well as improved water solubility of these inhibitors. We carried out the three component condensation reactions with 1,1-dimethylhydrazine, glycidol, and the platform heterocyclic esters **12** and **32** in isopropanol (Scheme 8). Unfortunately, we did not observe formation of any of the desired aminimide products, possibly due to the presence of an adjacent amino group in both esters. In contrast, condensation reactions carried out with ethyl aminobenzoate **35** afforded the desired aminimide **36** in good yield as a hydroscopic white solid.



Inhibition of RTA by the aminimide




Figure 4: Dose response for the aminimide

Compound 36, referred to as phenylamine-aminimide, proved to be very soluble in water and showed no inhibition of protein synthesis even at 1 mM concentrations. The ability to inhibit RTA activity was very strong, as shown in Figure 4. At this time the data suggest it has an IC_{50} of about 10 nM, making it at least 1000 times as potent as any small molecule inhibitor of ricin seen to date. One concern about the aminimides is that their low lipophilicity might retard cell uptake. At least one study (Boutis et al, 1978) shows aminimides are active against tumor lines, suggesting they can be taken into cells. Further design can be carried out to optimize uptake of this potent class of compounds.

TASK 2: Identify ligands for second ricin binding pocket

A. Computer Modeling studies

We acquired a program called LigBuilder to assist in inhibitor design (Wang et al, 2000). We had previously used the program ChemX which carries out virtual screens. That is it fits pre-existing molecules from a data base to the RTA active site test for stereo chemical fits; we used this program to find pteric acid for example. LigBuilder has a different philosophy - it is a "de novo" designer. It maps the active site for chemical properties like charge, hydrogen bond patterns, and hydrophobicity. It then fills the active site with simple complementary chemical groups, pharmacophores, from an internal library. It uses a genetic algorithm to search a large space and suggests a list of novel compounds that might bind strongly. It uses several established pharmacological criterion to rank these candidates.

We carried out a number of de novo building runs. One observation was that the program tends to design inhibitors that are too elaborate and would be synthetically difficult. However, the program is still very useful for defining recurrent pharmacophor "themes". For example, hundreds of potential ligands generated by LigBuilder placed an aromatic ring above the side chain of Trp 211, although in slightly different positions and orientations. To test if there is a natural site in the RTA active site for such a ring, we used the energy minimization routine from the X-ray suite CNS/XPLOR (Brunger, 1992). A test ring was positioned at several places identified by LigBuilder, and allowed to refine. The results are shown graphically in Figure 5. The RTA active site area is represented by the side chains of Tyr 80, Trp 211, and Val 256. Five representative benzene ring starting positions are shown as light gray hexagons and their energy refined positions as black hexagons. The tests suggest that the volume can accommodate an aromatic ring in a wide variety of positions and orientations and that there is no well defined global minimum to act as




Figure 5: Test of the energetics of a hydrophobic pharmacophore.

a constraint on inhibitor synthesis. An inhibitor will benefit from a hydrophobic group near here, but if need not be in a restricted orientation.

Another interesting pharmacophore is a positively charged group that sits near Glu 177 and Glu 180. We had suggested that the RTA mechanism might involve stabilization of an oxocarbenium ion (Ready et al, 1991), and this contention has been strengthened by the work of Schramm and his colleagues. They synthesized an RNA analog with a positively charged ring group to mimic the transition state and found it bound RTA with high affinity (Tanaka et al, 2001). Consistent with this notion, LigBuilder frequently designed ligands with a positively charged amine group in this area. We designed a simple ligand that incorporated these features: 9-oxo-7-deaza-guanine is the specificity group, a protonatable secondary amino group near the Glu 177 side chain, and a benzene ring in the hydrophobic site (shaded). The name of this compound is: 2-Amino-5-(2-benzylamino-ethyl)-3,7-dihydro-pyrrolo[3,2-d]pyrimidin-4-one, but we refer to it as 9DG-D5 (Figure 6). This compound lacks the pendant groups we eventually plan to add, which will bind to a putative "second pocket" on RTA. 9DG-D5 may be considered as a platform, plus linker, module. Energy minimization with CNS shows that all three moieties can be positioned in the RTA active site without torsional stress.

















Figure 6: A designed ligand, 9DG-D5

B. Crystallographic screening of shape-diverse sets


We have begun searching commercial compounds using the crystaLEAD, shape-diverse, screening method (Nienaber et al, 2000). We know that RTA has a primary specificity binding pocket which holds the adenine ring of natural substrates, and into which our inhibitor platform molecules bind. We plan to probe the vicinity for additional binding pockets that could interact favorably with pendant groups attached to the platform. We are screening for these pendants by soaking cocktails of potential "second site" molecules into RTA crystals and using X-ray diffraction to see if any bind to the protein. The cocktails are designed so that each has molecules sufficiently different in shape that X-ray crystallography can distinguish which molecule is binding to RTA. To date we have tested three cocktails; typically the stock solution contain 4 or 5 compounds each at 5 mM. These are diluted to roughly mM concentrations in the crystal screen. The three panels are shown below in Table 3. None to the screens has detected a strongly binding compound. The electron density maps show minor difference electron density "traffic" in the solvent areas, but nothing above 3σ inside the protein or in surface crevices.

Table 3: Shape diverse libraries screened by X-ray diffraction

Shape diverse library #	Shape-diverse Compound Structures
1	<div style="display: flex; justify-content: space-around; align-items: flex-start;"> <div style="text-align: center;">  <p>KeAZB024</p> </div> <div style="text-align: center;">  <p>2-mercaptobenzimidazole</p> </div> <div style="text-align: center;">  <p>2,4,6-triaminopyrimidine</p> </div> <div style="text-align: center;">  <p>2-aminophenol</p> </div> </div>
2	<div style="display: flex; justify-content: space-around; align-items: flex-start;"> <div style="text-align: center;">  <p>benzylamine</p> </div> <div style="text-align: center;">  <p>2-aminothiazoline</p> </div> <div style="text-align: center;">  <p>2-aminobenzimidazole</p> </div> <div style="text-align: center;">  <p>Piperazine</p> </div> </div>
3	<div style="display: flex; justify-content: space-around; align-items: flex-start;"> <div style="text-align: center;">  <p>Ke-TEL19</p> </div> <div style="text-align: center;">  <p>Ke-TMWH1-A</p> </div> <div style="text-align: center;">  <p>Ke-ACN2H1-A</p> </div> <div style="text-align: center;">  <p>2-Aminophenol</p> </div> <div style="text-align: center;">  <p>Ke-MDR04-A</p> </div> </div>

TASK 3: Prepare tripartite inhibitors joining best specificity pocket and second pocket moieties with appropriate linkers (months 9-24).

Synthesis of 2,5-Disubstituted pyridines



The pyridine-based side chains **37** were identified through computer modeling as potential ligands for the RTA second pocket. We proposed preparation of these side chains through coupling of 2-halopyridine derivatives with a 4-ethynylhydrocinamic acid derivative. We have prepared two such 2-halopyridine derivatives **39** and **42** (Scheme 9). Selective lithium-halogen exchange of 2,5-dibromopyridine (**38**) with butyl lithium, followed by addition of dimethylformamide affords the 2-bromopyridine derivative **40** in modest yield. Palladium-catalyzed coupling of **38** with benzophenone hydrazone leads to selective coupling at the 2-position to afford the coupled product **40**; however, coupling with the bromochloropyridine **41** gives the desired 2-chloropyridine **42** in good yield. Both **39** and **42** will be coupled to 4-ethynylhydrocinamic acid (R= COCH₃ and NHNH₂)

KEY RESEARCH ACCOMPLISHMENTS

- A modified assay for RTA/inhibitor studies has been established and validated.
- A synthesis for 9-deazazguanine able to accept a range of pendants at C7 has been worked out.
- The synthesis of substituted aminimides has been carried out very recently as a new class of ricin inhibitors.
- Phenylamine-aminimide is the most potent RTA inhibitor yet tested, with an IC_{50} of 10 nM (page 11).
- Computer modeling (LigBuilder) and energy minimization experiments have mapped parts of the RTA inhibitor binding surface
- A successful synthesis of 2,5-Disubstituted pyridines has initiated studies for "second site" inhibitor pendants.

REPORTABLE OUTCOMES

No papers from year one work have yet been prepared, but publishable work has been accomplished. The aminimide inhibitors are particularly exciting.

CONCLUSIONS

Year one initially involved assembling the research teams, reproducing past work with new researchers and then executing the research plan. We discovered that the synthetic strategy which led to our previous best compound, 8-methyl-9-oxoguanine, was not general to pendants other than the 8-methyl group. We compensated by expanding work on other platforms, especially 9-deazazguanine. This new platform was used in modeling experiments to generate a new idealized platform-linker concept; we found the new de novo drug design program, LigBuilder, was simple to use and generate useful insights into chemical classes that interact favorably with RTA. Perhaps the most exciting finding was the potency of the aminimide compounds. These peptide mimetics have been used as peptidase inhibitors. Their modular nature, coupling a wide range of commercially available esters, azides, and epoxides, made them attractive candidates for this project. Their synthesis proved more difficult than expected, however, which may account for the relative paucity of literature data for this apparently flexible chemical class. However, the great potency of our first simple model suggests we should divert some effort to optimizing this class of compounds; the unoptimized phenylamine-aminimide is roughly 4000 times more potent than any other inhibitor of RTA we have tested. X-ray studies are underway to analyze the binding of phenylamine-aminimide to RTA and to explain its potency. Our current hypothesis is that the aminimide zwitterionic nitrogens, of the form [$--N^- -- N^{+--}$], may interact with Arg

180 and Glu 177, respectively, in the RTA active site. We presume the X-ray analysis will show the phenylamine group binds in the specificity cavity or RTA; if this is so, we plan to incorporate starting material esters which are known to make favorable interactions with the RTA specificity site.

"So what?": The proposed inhibitor design project is making headway at the anticipated rate; that is, efforts to assemble a tripartite inhibitor are on schedule with some successes and some setbacks. The newly discovered, and as yet synthetically unrefined, phenylamine-aminimide has an IC_{50} that is in the range for true drugs. We will undertake studies to test if the compounds are taken up effectively by cells. It may be that future design for this chemical class will change from emphasizing potency against RTA to improving cell uptake. It seems quite likely that RTA antidotes can be created.

REFERENCES

- Boutis, L. Papageorgiou, A.; Toliou, T.; Kabara, J. J. (1978) Observations on the Antineoplastic Activity of Aminimides. *Curr. Chemother., Proc. Int. Congr. Chemother.* 1, 1213-1216.
- Brünger, A.T. X-PLOR version 3.1: A system for X-ray crystallography and NMR. Yale University Press, New Haven (1992).
- Chen, X.Y., Link, T.M., and Schramm, V.L. (1998) Ricin A-chain: kinetics, mechanism, and RNA stem-loop inhibitors. *Biochemistry* 37, 11605-11613.
- Endo, Y., Mitsui, K., Motizuki, M., and Tsurugi, K. (1987) The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. *J Biol Chem.* 262, 5908-5912.
- Loyd, A and Fletcher, M. (2001) Bin Laden's poison manual. *London Times*, November 16, Overseas Section.
- Miller, D.J, Ravikumar, K, Shen, H., Suh, J.K., Kerwin, S.M., and Robertus, J.D. (2002) Structure-Based Design and Characterization of Novel Platforms for Ricin and Shiga Toxin Inhibition. *J. Med. Chem.* 45, 90-98.
- Nienaber, V. L., Richardson, P. L., Klinghofer, V., Bouska, J. J., Giranda, V. L., and Greer, J. (2000) Discovering novel ligands for macromolecules using X-ray crystallographic screening *Nature biotech.* 18, 1105-1108.
- Olson, M.A., Carra, J.H., Roxas-Duncan, V., Wannemacher, R.W., Smith, L.A., and Millard, C.B. (2004) Finding a new vaccine in the ricin protein fold. *Protein Eng Des Sel.* (in press)

- Patil, V. D.; Townsend, L. B. (1971) Synthesis of Certain 2,7-Disubstituted Oxazolo[5,4-d]pyrimidines *J. Heterocycl. Chem.* **8**, 503-505.
- Peisach, E.; Casebier, D.; Gallion, S. L.; Furth, P.; Petsko, G. A.; Hogan, J. C.; Ringe, D. (1995) Interaction of a Peptidomimetic Aminimide Inhibitor with Elastase *Science* **269**, 66-69.
- Ready, M., Bird, S., Rothe, G. and Robertus, J.D. (1983) Requirements for Antiribosomal Activity of Pokeweed Antiviral Protein. *Biochem. Biophys. Acta* **740**, 19-28.
- Ready, M.P., Kim, Y. and Robertus, J.D. (1991) Site directed mutagenesis of ricin A chain and implications for the mechanism of action. *Proteins* **10**, 270-278.
- Rutenber, E. E.; McPhee, F.; Kaplan, A. P.; Gallion, S. L.; Hogan, J. H., Jr.; Craik, C. S.; Stroud, R. M. (1996) A New Class of HIV-1 Protease Inhibitor: The Crystallographic Structure, Inhibition and Chemical Synthesis of an Aminimide Peptide Isostere. *Bioorg. Med. Chem.* **4**, 1545-1558.
- Sekiya, M.; Suzuki, (1970) Azole series. III. Reactions of 2-acylamino-2-cyanoacetamides leading to 5-aminooxazole-4-carboxamides and to oxazolo[5,4-d]pyrimidines. *J. Chem. Pharm. Bull.* **18**, 2242-2246.
- Slagel, R. C. (1968) Aminimides. VI. Synthesis of Aminimides from carboxylic Acid Esters, Unsymmetrically Disubstituted Hydrazines, and Epoxides. *J. Org. Chem.* **33**, 1372-1378.
- Tanaka, K. S. E., Chen, X.-Y., Ichikawa, Y., Tyler, P. C., Furneaux, R. H., and Schramm, V. L. (2001) Ricin A-chain inhibitors resembling the oxacarbenium ion transition state (2001) *Biochemistry* **40**, 6845-6851.
- Taylor, E. C. and Young, W. B. (1995) Pyrrolo[3,4-d]pyrimidine folate analogues: Inverted analogues of the cytotoxic agent LY231514. *J. Org. Chem.* **60**, 7947-7952.
- Turchi, I. J.; Maryanoff, C. A. (1983) A new synthesis of oxazolo[5,4-d]pyrimid-7-ones. *Synthesis* **10**, 837-839.
- Wang, R., Gao, Y., and Lai, L. (2000) LigBuilder: a multi-purpose program for structure-based drug design. *J. Mol. Mod.* **6**, 498-516.
- Wellner, R. B., Hewetson, J. F., Poli, M. A. (1995) Ricin: Mechanism of action, detection, and intoxication *J. Toxicol, Toxin Rev.* **14**, 483-522.
- Yan, X., Hollis, T., Svinth, M., Day, P., Monzingo, A.F., Milne, G.W.A., and Robertus, J.D. (1997) Structure-based identification of a ricin inhibitor. *J. Mol. Biol.* **266**, 1043-1049.